Virtual darkness therapy for agitation in dementia
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether virtual darkness therapy (sitting in a dim, calming environment) can reduce agitation in people with dementia. It is designed for patients at NKS Olaviken hospital who have significant agitation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of dementia (any type or stage).
- You must be 50 years or older.
- You must have significant agitation (scoring 45 or more on a standard agitation scale).
- You must currently be a patient at NKS Olaviken gerontopsychiatric hospital.
- You cannot be completely blind or have severe problems with your red reflex (a specific eye exam).
- You cannot be taking melatonin supplements.
- You cannot have substantial pain (scoring 3 or more on a pain scale).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether light therapy can improve behavioral and psychological symptoms (such as agitation or aggression) in people with dementia. You may be eligible if you or your loved one is admitted to a specific inpatient unit at Mayo Clinic and has these symptoms.
This trial tests two new drugs (EXV-802 and EXV-801) to see if they can safely reduce moderate to severe agitation in people with Alzheimer's dementia. If you or a loved one has Alzheimer's and has been experiencing significant agitation for at least two weeks, this study may be an option.
This trial tests whether using a realistic doll can reduce agitation and aggressive behaviors in people with moderate to severe dementia during a hospital stay. It may help some patients feel calmer and more comfortable through structured interaction.
This trial tests whether virtual reality headsets showing hypnosis scenes can reduce agitation and resistance during bathing or toileting in people with Alzheimer's disease. It aims to make daily care calmer and less stressful for patients and caregivers.
This trial tests a skin patch that delivers a medicine called dexmedetomidine to help calm agitation in people with Alzheimer's disease. It might be an option for those living in a care facility who have had recent episodes of agitation.
This trial tests whether a virtual reality nature experience can help improve mood in people with early-to-moderate Alzheimer's disease. Participants will use a VR headset and a few apps at home, with a caregiver present, over several sessions.
Hear when a new Agitation in Dementia, Including Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.